Holen Sie sich die Stockscreener-App
18.96
1.94%
0.36
Handel nachbörslich:
19.06
0.10
+0.53%
Schlusskurs vom Vortag:
$18.60
Offen:
$18.55
24-Stunden-Volumen:
951.32K
Relative Volume:
1.18
Marktkapitalisierung:
$1.66B
Einnahmen:
$23.38M
Nettoeinkommen (Verlust:
$-155.22M
KGV:
-8.6575
EPS:
-2.19
Netto-Cashflow:
$-134.36M
1W Leistung:
-0.58%
1M Leistung:
-8.67%
6M Leistung:
-49.39%
1J Leistung:
-58.52%
1-Tages-Spanne:
$18.49
$19.59
1-Wochen-Bereich:
$16.95
$19.67
52-Wochen-Spanne:
$16.95
$46.40
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Vergleichen Sie IDYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
18.96 | 1.66B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
Ideaya Biosciences stock hits 52-week low at $17.28 By Investing.com - Investing.com Australia
Ideaya Biosciences stock hits 52-week low at $17.28 - Investing.com
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up – What’s Next? - Defense World
IDEAYA Announces Further Gilead Sciences Clinical Study Collabor - GuruFocus.com
IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform - Insider Monkey
Top 10 AI Trending News on Wall Street - Insider Monkey
IDEAYA Biosciences Partners With ATTMOS To Advance AI/ML-Driven Oncology Drug Discovery - Nasdaq
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accele - GuruFocus.com
Ideaya Biosciences stock hits 52-week low at $19.95 - Investing.com India
Ideaya Biosciences stock hits 52-week low at $19.95 By Investing.com - Investing.com South Africa
IDEAYA Biosciences, ATTMOS Collaborate to Advance Small Molecule Discovery for Undruggable Oncology Targets - Marketscreener.com
Can AI Finally Crack "Undruggable" Cancer Targets? IDEAYA's New Tech Partnership Aims to Revolutionize Oncology - StockTitan
IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets - PR Newswire
Rhumbline Advisers Has $2.92 Million Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Rule 5635(c)(4) - Nasdaq
IDEAYA Biosciences Grants Stock Options to 4 New Employees Under Inducement Plan - StockTitan
When the Price of (IDYA) Talks, People Listen - Stock Traders Daily
Fair Value analysis proves accurate as IDEAYA shares drop 41% in 10 months - Investing.com India
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month LowWhat's Next? - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results, Misses Expectations By $0.82 EPS - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Sets New 12-Month Low – Here’s Why - Defense World
IDEAYA Biosciences, Inc. SEC 10-K Report - TradingView
Fiera Capital Corp Has $30.44 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences' SWOT analysis: cancer therapy stock poised for pivotal year - Investing.com
How To Trade (IDYA) - Stock Traders Daily
IDEAYA announces proposed public offering of common stock and pre-funded warrants - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Trading Down 4.8%Time to Sell? - MarketBeat
IDEAYA Biosciences Stock Gains Momentum as Analysts Reaffirm Bullish Outlook - HPBL
IDEAYA Biosciences' (IDYA) "Overweight" Rating Reiterated at Stephens - MarketBeat
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA) - MSN
IDEAYA Biosciences (IDYA) Expected to Announce Earnings on Tuesday - MarketBeat
IDEAYA Biosciences Reports 2024 Financials and Business Update - TipRanks
WCM Investment Management LLC Buys Shares of 241,894 IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya Biosciences stock hits 52-week low at $21.02 By Investing.com - Investing.com Australia
Q1 Earnings Estimate for IDYA Issued By Leerink Partnrs - MarketBeat
IDEAYA BIOSCIENCES Earnings Results: $IDYA Reports Quarterly Earnings - Nasdaq
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss - MSN
Ideaya Biosciences falls as quarterly loss widens - TradingView
IDEAYA Biosciences Launching Gilead Trial Collaboration to Evaluate Trodelvy, IDE397 Combination in Lung Cancer - Marketscreener.com
IDEAYA announces expanded collaboration with Gilead Sciences - MSN
Ideaya Biosciences enters additional supply pact with Gilead for IDE397 - TipRanks
Amgen ends Ideaya cancer combination trial after partner unveils rival molecule - Fierce Biotech
IDEAYA Biosciences Q4 Loss Widens, Revenue Rises -February 13, 2025 at 06:59 am EST - Marketscreener.com
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q4 Collaboration Revenue of $7M - Marketscreener.com
IDEAYA Q4 Earnings: Massive $1.1B War Chest Fuels Breakthrough Cancer Drug Development - StockTitan
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - Nasdaq
Ideaya Biosciences stock hits 52-week low at $21.02 - MSN
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.39%
0.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):